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Abstract
Background Chronic kidney disease (CKD) is an impor-
tant public health problem. Most of the evidence on its
costs relates to patients receiving dialysis or kidney trans-
plants, which shows that, in these phases, CKD poses a
high burden to payers. Less evidence is available on the
costs of the predialytic phase.
Objective The aim of this study was to estimate the annual
cost of patients with CKD not receiving dialysis treatment,
using the Italian healthcare system perspective and a
prospective approach.
Methods A 3-year observational study (December 2010–
September 2014) was carried out to collect data on
resource consumption for 864 patients with CKD. Costs
were estimated for both patients who completed the follow-
up and dropouts.
Results The mean annual total (healthcare) cost per patient
equalled €2723 (95% confidence interval 2463.0–2983.3).
Disease severity (higher CKD stage), multiple comorbidi-
ties, dropout status and belonging to the southern region are
predictive of higher costs. Pharmaceuticals, hospitalisation,
and outpatient services account for 71.5, 18.8 and 9.7% of
total healthcare expenditure, respectively. Recent estimates
of Italian costs of patients receiving dialysis are nine times
the unit costs of CKD for patients estimated in this study.
Unit costs at stage 5 CKD (the highest level of severity)
equals 4.7 times the costs for patients at stage 1 CKD.
Conclusion Despite its limitations, this study provides
further evidence on the opportunity to invest in the first
phases of CKD to avoid progression and an increase in
healthcare costs.
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Key Points for Decision Makers
This 3-year observational study shows that
healthcare costs of patients with chronic kidney
disease (CKD) not receiving dialysis are, on average,
€2.7k.
The last stages of CKD account for 17–22% of unit
healthcare costs of patients receiving dialysis.
Policymakers should enhance all actions to postpone
patients starting on dialysis; this would imply
important savings for the healthcare system
The greater the severity of CKD, the higher the costs
of patients with CKD. The more patients are kept at
the initial stages, the higher the savings will be for
the healthcare system.
Early management of patients with CKD in the
predialysis stages, as well as the use of proper
preventive treatments, may in fact slow the
progression of kidney damage, including access to
dialysis, with consequent savings of economic
resources
1 Background
Chronic kidney disease (CKD) is an important public
health problem. In the US, CKD is the ninth leading cause
of death and affects more than 10% of the adult population.
Total US Medicare expenditure for CKD (excluding drugs)
accounts for 6% of all Medicare costs [1].
The literature relating to costs of CKD include different
contributions for end-stage renal disease (ESRD) that
requires renal replacement therapy (RRT) in the form of
dialysis or transplantation. These costs represent 2–3% of
the annual healthcare budget of public health systems [2].
The annual growth rate of dialysis costs has ranged from 6
through 12% over the past 2 decades in most developed
countries [3]. In Italy in 2001, it was estimated that 1.8% of
the total healthcare budget was spent on ESRD patients,
representing 0.083% of the general population [4].
According to more recent estimates, total healthcare
spending on ESRD has reached €2.1 billion in 2010 (i.e.
1.9% of the healthcare budget) and healthcare costs of
patients receiving dialysis range from €29.8K to €43.8K
depending on the techniques used (peritoneal dialysis vs.
haemodialysis) [5].
Costs in the earlier stage of CKD before dialysis are less
investigated. A paper published in 2009 on US Medicare
costs shows that the average cost per patient receiving
dialysis is 2.5 times the costs of patients with CKD, and the
average healthcare costs of patients with CKD is three
times the unit cost of patients covered by Medicare [6].
More recent research on the cost of CKD in Australia,
relying on a national longitudinal population-based study
of Australian adults with diabetes aged C 25 years, shows a
significant difference in the per-person annual direct
healthcare costs by CKD status—from $1829 for those
without CKD to $14,545 for those with stage 4 or 5 CKD,
where stages refer to decreasing glomerular filtration rate
(GFR) and range from 1 to 5 [7].
Another retrospective study on the population with
type 2 diabetes was carried out in Germany. The costs for
patients in stages 4 and 5 were 1.97 and 3.5 times,
respectively, the costs of patients in stage 3 [8]. In Italy, the
evidence on predialysis costs is also limited. A recent study
carried out in Tuscany (6.2% of the Italian population) in
2012 and 2013, and focusing on stage 4 and 5 CKD, pro-
duced estimated direct medical costs of €4352, i.e. 44% of
the overall social cost (€9855) [9]. A retrospective analysis
on prescriptions by 124 general practitioners (GPs) for
12,400 patients has estimated 2010 mean healthcare costs
per patient ranging from €450 in stages 1–2, to €3292 in
stage 5 [5]. More recent retrospective studies have been
carried out on regional databases and have investigated the
unit cost per patient in the predialysis and dialysis phases.
The first study, in the Piedmont region (7.2% of the Italian
population), compared incident-to-dialysis patients
observed for the 12 months before dialysis entrance
(€11,123) and established dialysis patients (€53,764) [10].
The second analysis was carried out in the Lombardy
Region (16.5% of the Italian population) and found a unit
healthcare cost per patient of €5239, €12,303 and €38,821
in the 12- to 24-month period before dialysis, 0–12-month
period before dialysis, and the first year of dialysis,
respectively [11].
However, none of these studies investigated the
healthcare costs of patients with CKD, using a prospective
approach and relying on data from specialist centres, which
may provide a more complete collection of healthcare
resources used than GPs.
2 Research Question and Methods
This research aims at filling the gap in the literature, i.e.
estimating the annual costs of patients with CKD not
receiving dialysis treatment, using the Italian healthcare
system perspective and relying on a prospective multi-
centre approach. The costs of patients with CKD includes
the costs of CKD and the costs of comorbidities that are
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possible consequences of CKD, but not the costs of
comorbidities not linked to the disease.
Patients aged[18 years with CKD (as defined based on
the Kidney Disease Outcomes Quality Initiative (K-DOQI)
guidelines [12]) in the predialysis phase were included in
the study. Patients with comorbidities with a life expec-
tancy of \1 year (e.g. advanced-phase malignancies,
advanced liver disease), patients enrolled in a clinical trial
(interventional study) receiving erythropoietin, vitamin D
or phosphate binders at the start of the survey, and renal
transplant recipients were not included in the study.
Dropouts included patients who had started dialysis or died
during the follow-up period, who had withdrawn consent,
and who had been lost to follow-up.
Data on resource consumption were collected through
an electronic case record form (e-CRF). Patients were
recruited in 24 centres (originally 26, but in one centre the
follow-up of all patients was interrupted for organisational
issues, and one centre did not enrol any subjects) in 15 of
the 21 Italian healthcare regions. Participating centres were
selected according to the following criteria: (1) speciali-
sation in nephrology; and (2) more than 20 patients visited
the centre per week. Patients were consecutively recruited
in order to limit selection bias. Sample size was determined
on the grounds of alleged secondary hyperparathyroidism
outcome in stage 4 patients since no other epidemiologic
data had been reported in the literature at the time of the
study design.
The follow-up lasted 3 years. For all participants,
defined as those patients who met the inclusion/exclusion
criteria after signing the informed consent, clinical and
healthcare consumption data were recorded. The recruit-
ment phase started on December 2010 and finished in
September 2011. The follow-up phase was terminated in
September 2014.
The study was also designed to collect data on produc-
tivity loss; however, despite 321 patients (36.4%) being
25–65 years of age, working loss days were collected for
nine patients only. Hence, productivity-loss data were not
included in the analysis.
The physician responsible filled in the form every
6 months, up to 36 months. Responders were asked to
collect data on (1) molecules, daily dosage, and treatment
days; (2) outpatient services, including visits, diagnostic
procedures and laboratory tests; and (3) inpatient services
and the relevant Diagnosis-Related Group (DRG) code.
Drug unit costs were calculated as a 2014 mean unit
price per dose (Drugs National Formulary), considering
different products per molecule (the e-CRF did not allow
responders to quote the brand name of the prescribed
product) and different possible distribution systems. In fact,
some drugs (e.g. new antidiabetic drugs or epoetins) may
be distributed as follows.
• By community pharmacies (ordinary distribution): list
price (net of discounts and co-payment) is paid by the
Italian National Health Service (NHS).
• Directly by health authorities: ex-factory price, net of
local discounts, is paid by the NHS. Local discounts
were not available and gross ex-factory price was used.
• By community pharmacies on behalf of health author-
ities: ex-factory price, net of local discounts is paid by
the NHS; pharmacies also receive a remuneration, as
defined by local agreements. Since many responders
did not distinguish between distribution by health
authorities and distribution by community pharmacies
on behalf of health authorities, we did not include the
remuneration paid to pharmacies; local discounts were
not available and gross ex-factory price was used.
For ordinarily distributed molecules with at least one
generic available, we used the minimum price per dose
since the NHS reimburses this cost.
Estimates of unit costs of ordinary and same-day (day-
hospital) hospitalisations relied on the relevant 2012
national fee-for-service [13]. Extra fees per day of stay
over the thresholds (maximum length of stay per DRG)
were considered. Outpatient services were also monetized
using the national fee-for-service [13].
If the patient’s follow-up lasted over 3 years (the actual
follow-up period could have been longer than 36 months if
the time interval between two visits was longer than 6
months) or less than 3 years but more than 1 year (some
patients dropped out), the annual cost per patient was
estimated as ‘daily cost 9 365’. However, if the patient’s
follow-up lasted less than 1 year (patients dropped-out),
the annual cost was estimated as ‘daily cost 9 follow-up
days’.
We performed descriptive statistics on unit costs per
patient according to (1) patients’ status, i.e. completed
follow-up or dropout; (2) starting-level disease severity,
measured through the GFR, ranging from 1 (lower CKD
stage) to 5 (higher CKD stage); (3) sex and age of
patients—10 age-group intervals were considered (18–24,
25–34, 35–44, 45–54, 55–64, 65–74, 70–74, 75–79, 80–84,
over 84 years); (4) geographical areas (northern region,
including Piedmont and Aosta Valley, Liguria, Lombardy,
Veneto, Friuli Venezia Giulia; central region, including
Tuscany, Marche, Latium, Abruzzo and Molise1; and
southern region, including Campania, Apulia and Basili-
cata, and Sardinia; (5) presence of comorbidities (hyper-
tension/diabetes/dyslipidaemia were the most frequent);
and (6) proteinuria at the date of recruitment. Statistical
1 Abruzzo and Molise are usually considered southern regions but we
preferred to include them in the central region group because they are
more similar to that group.
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significance of differences between values was tested using
the Kruskal–Wallis test.
The regression was performed using a linear model
ordinary last squares (OLS) with robust standard error
estimation to allow heteroskedasticity in residuals. The
explanatory variables were geographical area (north, cen-
tre, south), age-group class, sex, set of comorbidities (also
interacted with one another), severity at enrolment, pres-
ence of proteinuria at enrolment, and total time of
enrolment.
3 Results
Healthcare cost analysis was performed on 864 patients,
i.e. 884 patients recruited, net of 16 patients from one
centre that had not completed follow-up and 4 patients
whose costs were not filled in on the e-CRF. Overall, 586
patients completed the follow-up, whereas 278 patients
interrupted the study before the last visit (32.2%; ranging
from 51.4% in Veneto and 18% in Apulia and Basilicata)
(Table 1). Among the dropouts, 36.0% of patients began
dialysis treatment, 34.5% were lost to follow-up and 25.2%
died. The study population mainly consisted of males
(59.7%), and patients over 65 years of age accounted for
63.2% of the study population (18.6% were over 80 years
of age); mean age was 66.3 years (± 14.6 years). At the
time of enrolment, mean time from diagnosis was 7.0 years
(± 7.9 years) and only 0.7% of patients were at their first
nephrologist visit (data not reported in Table 1). Patients
with a starting GFR level in stages 1, 2, 3, 4 and 5 totalled
68, 156, 355 (167 in stage 3a and 188 in stage 3b), 206, and
79, respectively. Hypertension, hypercholesterolemia and
diabetes were the most frequent comorbidities, with 89.1%
of patients experiencing at least one of these comorbidities
and 107 patients (12.4%) being affected by all three.
Mean annual total (healthcare) cost per patient equalled
€2723 (Fig. 1). All differences between values (status of
patients, age, disease progression, comorbidities, starting
GFR level, proteinuria at recruitment, and region) were
found to be statistically significant according to the Krus-
kal–Wallis test, apart from the difference in unit costs
between the male and female populations.
The unit costs of patients who dropped out were almost
double those of patients who completed the follow-up.
Dropped-out patients starting dialysis and dead patients
during the follow-up period showed the highest mean
annual cost, confirming that proximity to dialysis and death
raises costs.
Disease progression produces an increase in costs. The
higher the starting CKD stage, the higher the healthcare
cost per patient. The largest difference between unit costs
was found when comparing stage 3b patients with stage 3a
patients (? 56%) and stage 4 patients with stage 3b patients
(? 62%) (Table 2). Stage 3 accounted for more than 40%
of patients.
Proteinuria also seems an important explanatory vari-
able of annual cost per patient. Costs for patients without a
proteinuria at the recruiting date were 25% less than
healthcare costs for patients with proteinuria (Table 2).
Patients with CKD often have other diseases, with dia-
betes, dyslipidaemia and hypertension being the most
important and frequent. Hypertension seems to have a
larger impact on unit costs; patients in whom renal failure
is associated with hypertension alone and hypertension
with diabetes show higher costs. However, not all comor-
bidities have an important effect on costs, e.g. unit costs of
patients with diabetes are lower than the average unit cost
(Table 2).
Mean annual cost per patient shows important variations
across regions. On average, the cost per patient is higher in
the southern and northern regions than in the central region
(Table 2), despite the proportion of dropped out patients
(who are, on average, costlier) being very similar across all
areas.
Ageing produces a rise in costs (Fig. 2), however the
growing trend shows an inflection point in the 70–74 age
group. Costs are higher for males (€2779), but the differ-
ence in the female population is negligible (?3%).
Pharmaceuticals, hospitalisation, and outpatients ser-
vices account for 71.5, 18.8 and 9.7% of total healthcare
expenditure, respectively (Table 3); hence, pharmaceuti-
cals are the most important component of healthcare
expenditure. Erythropoietins are the major component of
drug expenditure (accounting for 36.4% of total drug
expenditure), followed by antihypertensive drugs (18.7%)
and drugs for CKD [12.1%, including vitamin D (9.6%)
and chelating agents (2.5%)].
The contribution of hospitalisation to total costs is
higher for patients who dropped out than for patients who
completed the follow-up. More advanced is the starting
CKD stage, the higher the proportion of inpatient costs
(from 12.1% of total costs in stage 1 to 24% in stage 5)
(Table 3).
Table 4 illustrates the results of the multiple regression
model. The dependent variables are per capita total and
annual drug expenditure. Explanatory variables are listed in
column 1, while columns 2 and 3 include the reference
variable and other variables, respectively. In columns 4 and
5, correlation coefficients for total healthcare and drug
costs are reported. The explanatory power of the model is
not particularly high (R-squared ranges from 0.136 to
0.165). However, coefficients are significant for some
variables; a higher starting CKD stage, together with the
presence of three comorbidities, dropout status, and
belonging to the southern region are significantly
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correlated with both per capita healthcare and drug
expenditure. These variables seem to explain more
healthcare and drug expenditure than other variables (i.e.
age, sex, and the presence of proteinuria at recruitment).
4 Discussion
The present study is the first analysis that has investigated
the unit healthcare costs per patient with CKD before
dialysis, using a national, observational, multicentre,
prospective approach. The long follow-up period (3 years)
and the involvement of healthcare centres in different
regions allowed our analysis to produce a reasonable esti-
mate of the actual unit cost in Italy, despite not stating that
recruited patients represented all Italian patients with CKD
before dialysis as no epidemiological data on CKD were
available (incidence, prevalence, distribution of its various
stages, etc.). However, the multicentric nature of the study
and the fact that most regions were included, and recruited
centres were selected on the grounds of a minimum number
of patients who visited the centre, make this study more
Table 1 Characteristics of the recruited patients
Variable n (total = 864) % Variable N (total = 864) %
Follow-up completed vs. dropout Age groups, years
Follow-up completed 586 67.8 18–24 7 0.8
Dropout 278 32.2 25–34 25 2.9
Death 70 8.1 35–44 60 6.9
Dialysis 100 11.6 45–54 77 8.9
Lost to follow-up 96 11.1 55–64 149 17.2
Consent withdrawal 7 0.8 65–69 107 12.4
Inclusion criteria not satisfied 3 0.3 70–74 142 16.4
Others 2 0.2 75–79 145 16.8
80–84 110 12.7
[84 42 4.9
Region
Northern region 384 44.4
Piedmont and Aosta Valley 85 9.8 Starting CKD stage
Liguria 64 7.4 1 68 7.9
Lombardy 165 19.1 2 156 18.1
Veneto 35 4.1 3 355 41.1
Friuli VG 35 4.1 3a 167 19.3
Central region 279 32.3 3b 188 21.8
Tuscany 98 11.3 4 206 23.8
Marche 40 4.6 5 79 9.1
Latium 101 11.7
Abruzzo and Molise 40 4.6 Comorbidity
Southern region 201 23.3 None 94 10.9
Campania 45 5.2 Diabetes 17 2.0
Apulia and Basilicata 61 7.1 Dyslipidaemia 42 4.9
Sardinia 95 11.0 Hypertension 275 31.8
Diabetes? dyslipidaemia 17 2.0
Sex Diabetes? hypertension 109 12.6
Female 348 40.3 Dyslipidaemia? hypertension 203 23.5
Male 516 59.7 Diabetes? dyslipidaemia? hypertension 107 12.4
Starting proteinuria
Yes 396 45.8
No 365 42.2
Unkown 103 11.9
CKD chronic kidney disease
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representative of the population than other studies focussed
on a single region [10, 11].
Previous studies have investigated this topic using a
retrospective approach applied to prescriptions by GPs, or
single-region administrative databases. Despite the differ-
ent approach, we found some commonalties with other
studies, i.e. mean annual costs well below dialysis costs
[5, 10, 11] and an important increase in costs for more
severe disease stages [5].
The study has some limitations. Unit drug costs were
estimated as a weighted average price of all products
sharing the same molecule and formulation (prescriptions
Fig. 1 Mean annual total cost
per patient (€). DO dropouts,
CV coefficient of variation. *12
dropouts for reasons other than
death, dialysis, and lost to
follow-up
Table 2 Mean annual cost per patient according to their status (starting CKD level, proteinuria, comorbidities, geographic area) (€)
N Mean Median SD Coefficient
of variation (%)
SE 95% CI
Starting CKD stage
CKD 1 68 1169 865 1246 107 151.1 867.5 1470.8
CKD 2 156 1506 874 1845 123 147.7 1214.0 1797.7
CKD 3 355 2122 1074 2621 124 139.1 1848.5 2395.6
CKD 3a 167 1635 1019 1800 110 139.3 1359.9 1910.0
CKD 3b 188 2555 1084 3119 122 227.5 2106.1 3003.5
CKD 4 206 4147 2325 5554 134 387.0 3384.1 4910.0
CKD 5 79 5453 3859 5293 97 595.5 4267.0 6638.2
Proteinuria at recruitment
Yes 396 2937 1526 3781 129 190.0 2563.6 3310.7
No 365 2100 1045 2865 136 150.0 1805.2 2395.1
Unknown 103 4108 1840 6348 155 625.5 2867.4 5348.6
Comorbidities
Diabetes 17 1472 840 1576 107 382.3 661.9 2282.7
Dyslipidaemia 42 1845 1228 2003 109 309.0 1220.7 2468.8
Hypertension 275 2675 1023 4197 157 253.1 2176.4 3172.8
Diabetes? dyslipidaemia 17 2233 2014 1712 77 415.3 1353.0 3113.9
Diabetes? hypertension 109 3083 1662 3230 105 309.4 2469.4 3695.9
Hypertension? dyslipidaemia 203 2682 1406 3200 119 224.6 2239.5 3125.1
Diabetes? dyslipidaemia? hypertension 107 3865 2038 4998 129 483.2 2906.9 4822.7
Regions
Northern 384 2836 1237 4285 151 225.2 1964.5 2851.0
Central 279 2408 1155 3761 156 218.7 2405.7 3265.7
Southern 201 2946 1681 3236 110 228.3 2495.8 3396.0
CKD chronic kidney disease, SD standard deviation, SE standard error, CI confidence interval
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were recorded using the name of the molecule) in all
possible distribution settings (ordinary distribution, direct
distribution, distribution ‘on behalf’). It would have been
more appropriate to ask responders to complete the e-CRF
using the brand name instead of the name of the molecule;
however, responders preferred using the generic name of
the molecule. For outpatient and inpatient services,
national fees were used as a proxy of unit costs because
unit costs per patient were not available; however, fees do
not necessarily coincide with unit (full) costs, even if, in
principle, the Ministry of Health determined fees on the
grounds of cost estimates [10]. Furthermore, some
responders were rather imprecise in compiling the e-CRF.
In many cases, they quoted the wrong DRG number or
compiled a wrong drug dose. After consultation with the
responder, their records were eventually changed. The use
of an e-CRF may have led to recall bias for those data
orally reported by patients, i.e. hospitalisations and lost
work days. The former were further checked with the
physicians, while the latter were not used in the analysis.
Recall bias is possibly one of the drivers of important
differences in cost breakdowns. In our analysis, inpatient
costs accounted for 18.6–24% of total healthcare costs in
the advanced stages (rising to more than 26% for patients
who dropped out). Another study, which relied on a
regional administrative database, has reported an incidence
of hospitalisation costs higher than 75% in the 12 months
preceding dialysis entrance for incident-to-dialysis patients
[10].
5 Conclusions
Despite these limitations, this analysis has important policy
implications. First, the annual healthcare costs per patient
are approximately 10% of the healthcare costs of patients
receiving dialysis [5]. If the social perspective was adop-
ted, the difference could be even higher, considering
working days lost and informal care for patients receiving
dialysis. Hence, managing patients with CKD in order to
avoid dialysis should be a priority to better allocate scarce
resources. Second, one of the most important explanatory
Fig. 2 Mean annual cost per
patient according to the
different age groups (years) (€)
Table 3 Mean annual cost per
patient for drugs, and outpatient
and inpatient services (€)
Drugs (%) Outpatient (%) Inpatient (%) Total (%)
Patient status
All 1946.8 (71.5) 263.8 (9.7) 512.5 (18.8) 2723.1 (100.0)
Follow-up completed 1590.1 (76.0) 259.6 (12.4) 241.8 (11.6) 2091.5 (100.0)
Dropout 2698.7 (66.6) 272.5 (6.7) 1083.2 (26.7) 4054.5 (100.0)
Starting CKD stage
1 813.2 (69.6) 214.6 (18.4) 141.4 (12.1) 1169.2 (100.0)
2 1096.7 (72.8) 225.7 (15.0) 183.4 (12.2) 1505.8 (100.0)
3a 1196.7 (73.2) 192.0 (11.7) 246.3 (15.1) 1634.9 (100.0)
3b 1790.1 (70.1) 227.6 (8.9) 537.0 (21.0) 2554.8 (100.0)
4 3048.7 (73.5) 326.3 (7.9) 772.0 (18.6) 4147.0 (100.0)
5 3686.4 (67.6) 456.3 (8.4) 1309.8 (24.0) 5452.6 (100.0)
CKD chronic kidney disease
The Cost of Patients with Chronic Kidney Failure Before Dialysis
variables of CKD cost variations is CKD stage—the higher
the CKD stage, the higher the unit cost per patient. Unit
costs rocket when patients move from stage 3a to stage 3b
and from stage 3b to stage 4. An increased effort should be
made to maintain patients at levels 3a and 3b in order to
avoid cost escalations in the future.
Drugs represent the main component of CKD healthcare
costs. Considering that (1) they avoid future costs and (2)
drug unit costs also include pharmaceuticals for comor-
bidities (hypercholesterolemia, diabetes and dyslipi-
daemia), prevention of dialysis through an appropriate
management of drug therapy seems a value-for-money
investment.
Some variations in costs have been found across
regions; however, differences across areas are not as huge
as differences across CKD stages. Furthermore, geo-
graphical area was one of the most important explanatory
variables. This aspect has not been further investigated, but
it is likely that drug prescriptions should be better man-
aged. In the southern region where healthcare unit costs are
higher, the incidence of drugs on total healthcare expen-
diture is higher. Investment in drugs provides value for
money, but drugs should be appropriately managed to
avoid wasting resources.
In brief, this prospective observational study has pro-
vided important data to policy makers. Avoiding progres-
sion towards severe CKD and dialysis, together with a
more appropriate drug prescription, would imply thousands
of Euros saved, together with benefits to patients and
society as a whole.
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